Global CD47 (IAP) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global CD47 (IAP) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
CD47 (IAP) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CD47 (IAP) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Solid Tumor and Lymphoma are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for CD47 (IAP) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, CD47 (IAP) key companies include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab and ImmuneOnco, etc. Gilead, Innovent Biologics, Akeso, Inc are top 3 players and held % share in total in 2022.
CD47 (IAP) can be divided into CD47 Monoclonal Antibody, CD47 Double Antibody and CD47 Fusion Protein,, etc. CD47 Monoclonal Antibody is the mainstream product in the market, accounting for % share globally in 2022.
CD47 (IAP) is widely used in various fields, such as Solid Tumor, Lymphoma and Others,, etc. Solid Tumor provides greatest supports to the CD47 (IAP) industry development. In 2022, global % share of CD47 (IAP) went into Solid Tumor filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD47 (IAP) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
Segment by Type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
Solid Tumor
Lymphoma
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD47 (IAP) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, CD47 (IAP) introduction, etc. CD47 (IAP) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of CD47 (IAP) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for CD47 (IAP) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, CD47 (IAP) key companies include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab and ImmuneOnco, etc. Gilead, Innovent Biologics, Akeso, Inc are top 3 players and held % share in total in 2022.
CD47 (IAP) can be divided into CD47 Monoclonal Antibody, CD47 Double Antibody and CD47 Fusion Protein,, etc. CD47 Monoclonal Antibody is the mainstream product in the market, accounting for % share globally in 2022.
CD47 (IAP) is widely used in various fields, such as Solid Tumor, Lymphoma and Others,, etc. Solid Tumor provides greatest supports to the CD47 (IAP) industry development. In 2022, global % share of CD47 (IAP) went into Solid Tumor filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD47 (IAP) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
Segment by Type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
Segment by Application
Solid Tumor
Lymphoma
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD47 (IAP) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, CD47 (IAP) introduction, etc. CD47 (IAP) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of CD47 (IAP) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices